Skip to main content
LMAT
NASDAQ Industrial Applications And Services

LeMaitre Vascular Q2 2026: Sales Climb 10%, EPS Jumps 23%, Dividend Raised, Guidance Set

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$92.25
Mkt Cap
$2.417B
52W Low
$79.395
52W High
$118.01
52W Position info
16% above low
Off High info
22% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

LMAT sits 16% above its 52-week low of $79.395.

Summary

LeMaitre Vascular reported Q2 2026 sales of $70.4 million (+10% YoY) and EPS of $0.74 (+23%), declared a $0.25 dividend, and provided Q3 and full-year guidance. The quarter was driven by a 34% surge in Artegraft sales and meaningful margin expansion.


Key Events · Earnings and Guidance · LMAT

  • Q2 2026 Results Beat on Profitability

    Sales of $70.4M (+10% YoY) came in just shy of the $70.97M consensus, but EPS of $0.74 (+23%) topped expectations. Gross margin expanded 210 bps to 72.1%, and operating income rose 26% to $20.4M.

  • Artegraft Drives Growth

    Artegraft sales surged 34% in Q2, now representing 21% of total sales. The product is approved in 56 countries, and the international launch is gaining speed.

  • Dividend Increased to $0.25/Share

    The Board declared a quarterly dividend of $0.25 per share, payable September 3, 2026, to shareholders of record on August 20, 2026.

  • Q3 and Full-Year Guidance Issued

    Q3 guidance: sales $66.3M-$68.3M (midpoint $67.3M, +10% YoY), EPS $0.66-$0.71. Full-year guidance: sales $274.3M-$278.3M (midpoint $276.3M, +11% YoY), EPS $2.84-$2.94.


Analysis · LMAT · Industrial Applications And Services

A strong second quarter for LeMaitre Vascular featured double-digit sales and earnings growth, fueled by the international rollout of Artegraft and disciplined operating leverage. Gross margin widened 210 basis points to 72.1%, while operating income advanced 26% on a flat headcount. The board declared a $0.25 quarterly dividend and issued Q3 and full-year guidance that signals sustained momentum. With $376 million in cash, the company retains ample strategic flexibility. Although the top line slightly missed the consensus estimate of $70.97 million, profitability exceeded expectations, and the Q3 sales guidance midpoint sits below the current quarter's run rate, which may moderate investor enthusiasm.

At the time of this filing, LMAT was trading at $92.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $79.40 to $118.01. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LMAT - Latest Insights

LMAT
Aug 04, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $92.00
Real-time Price: $92.25 info
Change: +$0.250 (+0.27%) info
Market Cap: $2.417B info
LMAT
May 11, 2026, 6:22 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $101.74
Real-time Price: $92.25 info
Change: -$9.49 (-9%) info
Market Cap: $2.417B info
LMAT
May 06, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $112.00
Real-time Price: $92.25 info
Change: -$19.75 (-18%) info
Market Cap: $2.417B info
LMAT
May 05, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $112.00
Real-time Price: $92.25 info
Change: -$19.75 (-18%) info
Market Cap: $2.417B info
LMAT
May 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $112.00
Real-time Price: $92.25 info
Change: -$19.75 (-18%) info
Market Cap: $2.417B info